论文部分内容阅读
本研究应用PHA、抗CD3单抗(aCD3)和rIL-2共同刺激人外周血单个核细胞(PBMC),诱生、扩增新型抗肿瘤效应细胞PHA-aCD3LAN,并与PHA-LAk和CD3AK细胞在某些生物学特性方面进行了比较,结果表明,PHA、aCD3和IL-2具有协同增强效应、使PHA-aCD3LAK细胞的增殖能力、细胞毒活性、mIL-2Ra的表达水平及对IL-2的利用均高于PHA-LAK和CD3AK细胞;三组效应细胞均为异质性细胞群体,均以CD3~+ CD8~+T细胞为主,而PHA-aCD3LAK的CD8~+细胞百分率高于其它两组细胞.采用PHA-aCD3LAK可进一步提高LAK细胞的数量和活性,具有重要的临床应用前景
In this study, PHA, anti-CD3 monoclonal antibodies (aCD3) and rIL-2 were used to stimulate human peripheral blood mononuclear cells (PBMCs) and induced and expanded novel anti-tumor effector cells PHA-aCD3LAN and PHA-LAk and CD3AK cells. Comparing certain biological characteristics, the results show that PHA, aCD3 and IL-2 have a synergistic enhancing effect, proliferating ability of PHA-aCD3LAK cells, cytotoxic activity, expression level of mIL-2Ra and IL-2. The utilization rate of both cells was higher than that of PHA-LAK and CD3AK cells; the three groups of effector cells were all heterogeneous cell populations, and all of them were mainly CD3~+ CD8~+ T cells, while the percentage of CD8~+ cells of PHA-aCD3LAK was higher than others. Two groups of cells. The use of PHA-aCD3LAK can further increase the number and activity of LAK cells, and has important clinical application prospects.